Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8051 to 8100 of 8117 results

  1. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]

    In development [GID-TA11514] Expected publication date: 25 September 2024

    Technology appraisal guidance
    In development

  2. Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]

    In development [GID-TA10653] Expected publication date: 22 May 2024

    Technology appraisal guidance
    In development

  3. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]

    In development [GID-TA10979] Expected publication date: 26 June 2024

    Technology appraisal guidance
    In development

  4. Obesity: clinical assessment and management (QS update)

    In development [GID-QS10183] Expected publication date: TBC

    Quality standard
    In development

  5. Obesity: prevention and lifestyle management (QS update)

    In development [GID-QS10184] Expected publication date: TBC

    Quality standard
    In development

  6. Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID5085]

    In development [GID-TA10962] Expected publication date: 17 July 2024

    Technology appraisal guidance
    In development

  7. Vamorolone for treating Duchenne muscular dystrophy [ID4024]

    In development [GID-TA11135] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088]

    In development [GID-TA10980] Expected publication date: 17 July 2024

    Technology appraisal guidance
    In development

  9. Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma ID2725

    In development [GID-TA10571] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

    In development [GID-TA10165] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Topical Antimicrobial dressings for wound care: Late stage assessment

    In development [GID-HTE10041] Expected publication date: TBC

    Health technology evaluations
    In development

  12. Teclistamab for treating relapsed or refractory multiple myeloma after 3 treatments (Review of TA869) [ID6333]

    In development [GID-TA11418] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  13. Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]

    Awaiting development [GID-TA11491] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]

    Awaiting development [GID-TA11326] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Venglustat for treating gangliosidoses in people 2 years and over [ID6358]

    Awaiting development [GID-TA11396] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  16. Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]

    In development [GID-TA11228] Expected publication date: 25 September 2024

    Technology appraisal guidance
    In development

  17. Elranatamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID4026]

    In development [GID-TA10918] Expected publication date: 05 June 2024

    Technology appraisal guidance
    In development

  18. Abaloparatide for treating osteoporosis in postmenopausal women [ID882]

    In development [GID-TA10071] Expected publication date: TBC

    Technology appraisal guidance
    In development

  19. Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212

    In development [GID-TA11203] Expected publication date: 05 March 2025

    Technology appraisal guidance
    In development

  20. Cladribine for treating relapsing multiple sclerosis ID6263

    In development [GID-TA11293] Expected publication date: 05 February 2025

    Technology appraisal guidance
    In development

  21. Pegzilarginase for treating arginase-1 deficiency [ID4029]

    In development [GID-HST10054] Expected publication date: 30 October 2024

    Highly specialised technologies guidance
    In development

  22. Heart failure algorithms for remote monitoring in people with cardiac implantable electronic device: diagnostics consultation

    We are listening to your views on this Diagnostics guidance. Comments close 4 June 2024.

    Diagnostics guidance
    In consultation

  23. Transperineal laser ablation (TPLA) for treating lower urinary tract symptoms of benign prostatic hyperplasia using a ultra-micro invasive approach.

    Awaiting development [GID-IPG10268] Expected publication date: 12 December 2024

    Interventional procedures guidance
    Awaiting development

  24. SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]

    In development [GID-TA11355] Expected publication date: 09 July 2024

    Technology appraisal guidance
    In development

  25. Guselkumab for treating moderately to severely active ulcerative colitis ID6237

    In development [GID-TA11247] Expected publication date: TBC

    Technology appraisal guidance
    In development

  26. Pneumonia: diagnosis and management (update)

    In development [GID-NG10357] Expected publication date: TBC

    NICE guideline
    In development

  27. Menopause: diagnosis and management

    In development [GID-NG10241] Expected publication date: TBC

    NICE guideline
    In development

  28. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)

    In development [GID-NG10216] Expected publication date: TBC

    NICE guideline
    In development

  29. Electrically stimulated intravesical therapy for Interstitial Cystitis

    Awaiting development [GID-IPG10362] Expected publication date: 29 January 2025

    Interventional procedures guidance
    Awaiting development

  30. Guselkumab for previously treated moderately to severely active Crohn's disease ID6238

    In development [GID-TA11245] Expected publication date: TBC

    Technology appraisal guidance
    In development

  31. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]

    In development [GID-TA11369] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  32. Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy) [ID6369]

    In development [GID-TA10977] Expected publication date: TBC

    Technology appraisal guidance
    In development

  33. Selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma [ID3797]

    In development [GID-TA10646] Expected publication date: 15 May 2024

    Technology appraisal guidance
    In development

  34. Exagamglogene autotemcel for treating sickle cell disease [ID4016]

    In development [GID-TA11249] Expected publication date: 17 July 2024

    Technology appraisal guidance
    In development

  35. Depression

    All NICE products on depression. Includes any guidance and quality standards.

    Topic page

  36. Olorofim for treating invasive fungal infections in people 16 years and over TS ID 11983

      Status ...

    Technology appraisal guidance
    Topic selection

  37. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]

    In development [GID-TA11318] Expected publication date: TBC

    Technology appraisal guidance
    In development

  38. Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028]

    In development [GID-TA10917] Expected publication date: TBC

    Technology appraisal guidance
    In development

  39. Drug eluting stents for treating coronary heart disease: late stage assessment

    In development [GID-HTE10039] Expected publication date: TBC

    Health technology evaluations
    In development

  40. Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]

    In development [GID-TA11047] Expected publication date: 21 August 2024

    Technology appraisal guidance
    In development

  41. Fertility problems: assessment and treatment

    In development [GID-NG10263] Expected publication date: 29 May 2025

    NICE guideline
    In development

  42. Endometriosis: diagnosis and management - diagnosing endometriosis

    In development [GID-NG10392] Expected publication date: 10 July 2024

    NICE guideline
    In development

  43. Palopegteriparatide for treating chronic hypoparathyroidism ID6380

    In development [GID-TA11454] Expected publication date: TBC

    Technology appraisal guidance
    In development

  44. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]

    In development [GID-TA11480] Expected publication date: 13 November 2024

    Technology appraisal guidance
    In development

  45. Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]

    Awaiting development [GID-TA10752] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  46. Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 23 May 2024.

    Technology appraisal guidance
    In consultation

  47. Novel home-testing devices for diagnosing obstructive sleep apnoea/hypopnoea syndrome

    In development [GID-DG10074] Expected publication date: 11 September 2024

    Diagnostics guidance
    In development

  48. Heart failure algorithms for remote monitoring in people with cardiac implantable electronic device

    In development [GID-DG10080] Expected publication date: 22 August 2024

    Diagnostics guidance
    In development

  49. Adrenal insufficiency: identification and management

    In development [GID-NG10237] Expected publication date: 28 August 2024

    NICE guideline
    In development

  50. Type 2 diabetes in adults: management (medicines update)

    In development [GID-NG10336] Expected publication date: 19 June 2025

    NICE guideline
    In development